MedPath

Hydrocortisone Iodoquinol

Hydrocortisone 1% - lodoquinol 1% Cream

Approved
Approval ID

e468f033-4bf8-4786-92be-09d230065d9c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 12, 2023

Manufacturers
FDA

Westminster Pharmaceuticals, LLC

DUNS: 079516651

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Hydrocortisone and Iodoquinol

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69367-286
Product Classification
G
Generic Name
Hydrocortisone and Iodoquinol
Product Specifications
Route of AdministrationTOPICAL
Effective DateMay 12, 2023
FDA Product Classification

INGREDIENTS (12)

IODOQUINOLActive
Quantity: 10 mg in 1 g
Code: 63W7IE88K8
Classification: ACTIB
HYDROCORTISONEActive
Quantity: 10 mg in 1 g
Code: WI4X0X7BPJ
Classification: ACTIB
CETYL ALCOHOLInactive
Code: 936JST6JCN
Classification: IACT
MINERAL OILInactive
Code: T5L8T28FGP
Classification: IACT
GLYCERYL STEARATE SEInactive
Code: FCZ5MH785I
Classification: IACT
STEARYL ALCOHOLInactive
Code: 2KR89I4H1Y
Classification: IACT
XANTHAN GUMInactive
Code: TTV12P4NEE
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
PEG-100 STEARATEInactive
Code: YD01N1999R
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
PHENOXYETHANOLInactive
Code: HIE492ZZ3T
Classification: IACT
WHITE PETROLATUMInactive
Code: B6E5W8RQJ4
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 5/12/2023

PRINCIPAL DISPLAY PANEL - 28.4 g Tube Carton

NDC 69367-286-01
Rx Only

Hydrocortisone 1%-Iodoquinol 1% Cream

Westminster
Pharmaceuticals

Net Wt 1 oz (28.4 g)

PRINCIPAL DISPLAY PANEL - 28.4 g Tube Carton

DESCRIPTION SECTION

LOINC: 34089-3Updated: 5/12/2023

DESCRIPTION

Each gram contains 10 mg of hydrocortisone and 10 mg of iodoquinol in a vehicle consisting of: cetyl alcohol, glycerin, glyceryl stearate SE, mineral oil, PEG-100 stearate, phenoxyethanol, purified water, stearyl alcohol, white petrolatum, xanthan gum.

Paraben Free.

Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11β)-] with the molecular formula C21H30O5) and is represented by the following structural formula:

Chemical Structure

and iodoquinol, 5, 7-diiodo-8-quinolinol (C9H5I2NO) is represented by the following structural formula:

Chemical Structure

Hydrocortisone is an anti-inflammatory and antipruritic agent, while iodoquinol is an antifungal and antibacterial agent.

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 5/12/2023

CLINICAL PHARMACOLOGY

Hydrocortisone has an anti-inflammatory, antipruritic and vasoconstrictive properties. While the mechanism of anti-inflammatory activity is unclear, there is evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and the therapeutic efficacy in humans lodoquinol has both antifungal and antibacterial properties.

Pharmacokinetics

The extent of the percutaneous absorption of topical steroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Hydrocortisone can be absorbed from normal intact skin. Inflammation and/or other inflammatory disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, hydrocortisone is metabolized in the liver and most body tissue to hydrogeneted and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone. There are no data available regarding the percutaneous absorption of iodoquinol; however, following oral administration, 3-5% of the dose was recovered in the urine as glucuronide.

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 5/12/2023

PRECAUTIONS

NOT FOR OPHTHALMIC USE.

KEEP OUT OF REACH OF CHILDREN.

Avoid contact with eyes, lips and mucous membranes.

Information for Patients

If irritation develops, the use of this product should be discontinued and appropriate therapy instituted. Staining of the skin, hair and fabrics may occur. Not intended for the use on infants or under diapers of occlusive dressings. If extensive areas are treated or if the occlusive dressing technique is used, the possibility exists of increased systemic absorption of the corticosteroid, and suitable precautions should be taken.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.

Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if iodoquinol is present in the diaper or urine. Prolonged use may result on overgrowth of non- susceptible organisms requiring appropriate therapy.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term animal studies for carcinogenic potential have not been performed on this product to date. In vitro studies to determine mutagenicity with hydrocortisone have revealed negative results. Mutagenicity studies have not been performed with iodoquinol.

Pregnancy

Category C

Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

STORAGE AND HANDLING SECTION

LOINC: 44425-7Updated: 5/12/2023

STORAGE

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Keep container tightly closed.

NOTICE

Protect from freezing and excessive heat.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Hydrocortisone Iodoquinol - FDA Drug Approval Details